AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis
AbbVie (NYSE: ABBV) and Boehringer Ingelheim's Skyrizi performed better than Novartis' (NYSE: NVS) Cosentyx in a head-to-head late stage clinical trial in patients with the plaque psoriasis, an autoimmune skin disease.
After 16 weeks of treatment, Skyrizi was deemed non-inferior to Cosentyx -- the clinical trial way of saying "not worse than" -- with 74% of patients taking Skyrizi having at least a 90% improvement in the Psoriasis Area and Severity Index (PASI 90) compared to the start of the study, while 66% of patients taking Cosentyx achieved PASI90.
After a year of treatment, the efficacy of the drugs had separated with 87% of the patients taking Skyrizi reaching PASI 90, statistically better than the 57% of the patients taking Cosentyx who met the goal.
Source Fool.com
